Can you advertise Botox by name in Australia?
CompliGUARD reviews this compliance area against TGA · AHPRA · FSANZ · ACCC frameworks for Australian health brands — here's what the regulations say.
No. Botulinum toxin products are Schedule 4 prescription-only medicines, and advertising a prescription-only medicine to the general public is prohibited outright under the Therapeutic Goods Act 1989 — naming the brand in a public post, on a price list or on a website is a breach regardless of how the rest of the content is worded.
The rule: Therapeutic Goods Act 1989, s.42DL; Therapeutic Goods Advertising Code 2021; Poisons Standard Schedule 4
Advertisements directed to the public must not refer to substances in Schedules 4 or 8 of the Poisons Standard. Botulinum toxin products sit in Schedule 4. The prohibition covers the brand name and any reference that makes the specific product identifiable without naming it. This is a TGA obligation, not an Ahpra one — a cosmetic clinic that tidies up its Ahpra position and leaves the product names in place is still exposed, before a different regulator, with a separate penalty regime. Ahpra's guideline for higher risk non-surgical cosmetic procedures reinforces this at s.1.5 and s.5.1: where a procedure involves a prescription-only medicine, TGA requirements apply in addition to everything else in that guideline.
What this means in practice
- Brand names are out of public-facing content — including 'Botox', 'Dysport' and 'Xeomin' — on websites, social posts, stories, price lists, booking pages and paid ads.
- Use the procedure, not the product. 'Anti-wrinkle injections' and 'cosmetic injectables' describe the treatment without naming a scheduled substance. They remain subject to every other obligation in the cosmetic advertising guideline.
- Identifiable references still count. Dropping the brand name but leaving context that makes the product unmistakable does not cure the breach.
- Check the hashtags and the alt text. A prohibited reference in a hashtag, an image caption or a page title is still an advertisement to the public.
- Price lists are advertising. A treatment menu naming a prescription-only product on a public page engages both s.42DL and the price information requirements.
Common mistakes
Assuming the Ahpra cleanup is the whole job
A clinic archives its before-and-after posts, fixes its testimonials, and leaves 'Botox' in the website navigation. The Ahpra exposure is reduced; the TGA exposure is untouched.
Audit for prescription-only product references as a separate pass, across the website, social profiles, price lists and paid advertising.
Treating the brand name as a search term you cannot give up
The commercial instinct is that patients search the brand. Retaining it to capture that demand is a breach of s.42DL regardless of the commercial rationale.
Use the generic procedure terms, which carry the same search intent and are the conventional compliant alternative.
Believing a practitioner-only or educational framing fixes it
The test is whether the content is objectively directed to the public, not how it is labelled. An 'education' tag on a public post does not change who can see it.
Apply the restriction to anything publicly accessible, and gate genuinely practitioner-directed material behind a verified practitioner login.
Compliant vs non-compliant example
❌ NON-COMPLIANT
Assuming the Ahpra cleanup is the whole job
✅ COMPLIANT
Audit for prescription-only product references as a separate pass, across the website, social profiles, price lists and paid advertising.
The enforcement context
The TGA requested removal of over 13,700 unlawful advertisements from digital platforms in 2024–25. Therapeutic goods used in cosmetic procedures is one of the TGA's stated compliance priority focus areas from 1 January 2026. Maximum civil penalties for advertising breaches reach $15.65 million for corporations and $1.565 million for individuals, with infringement notices used for lower-level matters.
Before you publish, check it.
CompliGUARD reviews cosmetic procedure advertising against the Therapeutic Goods Advertising Code 2021, the prescription medicine advertising restrictions and the Ahpra cosmetic procedures guidelines in a single pass, flagging prescription-only references separately from practitioner advertising breaches so each is remediated properly.
Start free reviewRelated questions
Regulatory references
- Therapeutic Goods Act 1989 — s.42DL, s.42DLB
- Therapeutic Goods Advertising Code 2021
- Poisons Standard — Schedule 4
- Ahpra Guidelines for advertising higher risk non-surgical cosmetic procedures, in effect 2 September 2025 — s.1.5, s.4.3, s.5.1